MedPath

BAYER AG

BAYER AG logo
🇩🇪Germany
Ownership
Public
Established
1863-08-01
Employees
99.7K
Market Cap
$30.1B
Website
http://www.bayer.com

Effectiveness of Low Dose Aspirin in Decreasing the Chance Getting Stomach and Intestine Cancer

Completed
Conditions
Gastrointestinal Cancer
Interventions
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
First Posted Date
2019-09-09
Last Posted Date
2022-04-19
Lead Sponsor
Bayer
Target Recruit Count
99999
Registration Number
NCT04081831
Locations
🇭🇰

University of Hong Kong, Hong Kong, Hong Kong

A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

Phase 1
Completed
Conditions
Advanced Solid Tumors
Interventions
Drug: BAY2416964
First Posted Date
2019-08-28
Last Posted Date
2024-03-06
Lead Sponsor
Bayer
Target Recruit Count
78
Registration Number
NCT04069026
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Greenville Health System, Greenville, South Carolina, United States

🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

and more 14 locations

A Follow-up Physician Survey to Evaluate Physician Knowledge of Safety and Safe Use Information for Aflibercept Administered by Intravitreal Injection in Europe

Completed
Conditions
Ophthalmology, Macular Degeneration
Interventions
Other: Physician questionnaire
First Posted Date
2019-08-26
Last Posted Date
2021-04-08
Lead Sponsor
Bayer
Target Recruit Count
454
Registration Number
NCT04067583
Locations
🇩🇪

Many locations, Multiple Locations, Germany

Bioequivalence Study for Acarbose/Metformin FDC

Phase 1
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Acarbose/Metformin FDC(BAY81-9783)
Drug: Glucobay
Drug: Glucophage
First Posted Date
2019-08-22
Last Posted Date
2020-04-13
Lead Sponsor
Bayer
Target Recruit Count
24
Registration Number
NCT04065581
Locations
🇨🇳

Zhongshan Hospital, Fudan University, Shanghai, China

Study in Patients Suffering From Heartburn and Backward Flow of Stomach Liquid Into the Esophagus

Phase 2
Completed
Conditions
Functional Gastrointestinal Disorders
Interventions
Drug: STW5 (Iberogast®, BAY98-7411)
Drug: Placebo
First Posted Date
2019-08-16
Last Posted Date
2019-09-19
Lead Sponsor
Bayer
Target Recruit Count
64
Registration Number
NCT04059900
Locations
🇩🇪

Many locations, Multiple Locations, Germany

Study to Learn More About the Onset of Effect of Iberogast in Patients Suffering From Abnormal Stomach and Intestine Function

Completed
Conditions
Functional Gastrointestinal Disorders
First Posted Date
2019-08-16
Last Posted Date
2019-09-19
Lead Sponsor
Bayer
Target Recruit Count
272
Registration Number
NCT04059783
Locations
🇩🇪

Many locations, Multiple Locations, Germany

Study to Learn More About the Stomach and Intestine Complaints of Children Aged From 3 to 14 Years

Completed
Conditions
Functional Gastrointestinal Disorders
First Posted Date
2019-07-23
Last Posted Date
2019-09-19
Lead Sponsor
Bayer
Target Recruit Count
1032
Registration Number
NCT04029376
Locations
🇩🇪

Many locations, Multiple Locations, Germany

Study to Test the Safety of Increasing Multiple Doses of BAY2328065 Given by Mouth, How the Drug is Tolerated and Acts in the Human Body of Healthy Male Participants. Alteration of the Study Drug Effects by Another Drug and the Availability of the Drug Given in Different Formulations is Also Tested.

Phase 1
Completed
Conditions
Endometriosis
Interventions
Drug: BAY2328065 tablet
Drug: BAY2328065 LSF
Drug: Placebo tablet
Drug: Placebo LSF
Drug: Midazolam
First Posted Date
2019-07-19
Last Posted Date
2020-11-23
Lead Sponsor
Bayer
Target Recruit Count
50
Registration Number
NCT04027192
Locations
🇩🇪

CRS Clinical Research Services Berlin GmbH, Berlin, Germany

Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)

Phase 1
Completed
Conditions
Hemophilia A
Interventions
Biological: Damoctocog-alfa-pegol (BAY94-9027, Jivi)
Biological: Rurioctocog alfa pegol (Adynovi)
First Posted Date
2019-07-11
Last Posted Date
2020-12-21
Lead Sponsor
Bayer
Target Recruit Count
18
Registration Number
NCT04015492
Locations
🇧🇬

SHATHD Spec. Hospi. for Active Treatm. of Haematol. Dis. EAD, Sofia, Bulgaria

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090

Phase 3
Active, not recruiting
Conditions
Retinopathy of Prematurity (ROP)
Interventions
Procedure: Laser photocoagulation
Drug: Eylea (Aflibercept, BAY86-5321)
First Posted Date
2019-07-10
Last Posted Date
2024-12-05
Lead Sponsor
Bayer
Target Recruit Count
96
Registration Number
NCT04015180
Locations
🇧🇷

Hospital das Clínicas de Botucatu - UNESP Botucatu, Botucatu, Sao Paulo, Brazil

🇧🇷

Unifesp/Epm, São Paulo, Sao Paulo, Brazil

🇧🇬

UMHAT Sveti Georgi, Plovdiv, Bulgaria

and more 52 locations
© Copyright 2025. All Rights Reserved by MedPath